|
Condensed Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified |
3 Months Ended | |
|---|---|---|
|
Mar. 31, 2015
|
Mar. 31, 2014
|
|
| Revenue: | ||
| Licence fees, from a related party | $ 500us-gaap_Revenues | $ 0us-gaap_Revenues |
| Operating expenses: | ||
| Research and development | 1,642us-gaap_ResearchAndDevelopmentExpense | 4,487us-gaap_ResearchAndDevelopmentExpense |
| Research and development - licenses acquired | 7,439us-gaap_ResearchAndDevelopmentInProcess | 0us-gaap_ResearchAndDevelopmentInProcess |
| General and administrative | 3,490us-gaap_GeneralAndAdministrativeExpense | 2,095us-gaap_GeneralAndAdministrativeExpense |
| Total operating expenses | 12,571us-gaap_OperatingExpenses | 6,582us-gaap_OperatingExpenses |
| Loss from operations | (12,071)us-gaap_OperatingIncomeLoss | (6,582)us-gaap_OperatingIncomeLoss |
| Other income (expense): | ||
| Interest and other income | 82us-gaap_InvestmentIncomeInterest | 178us-gaap_InvestmentIncomeInterest |
| Interest expense | (331)fbio_AccretionAndInterestExpenses | (966)fbio_AccretionAndInterestExpenses |
| Change in fair value of investments | (215)fbio_ChangeInFairValueOfShortTermInvestments | 0fbio_ChangeInFairValueOfShortTermInvestments |
| Total other income (expense) | (464)us-gaap_NonoperatingIncomeExpense | (788)us-gaap_NonoperatingIncomeExpense |
| Net loss | (12,535)us-gaap_ProfitLoss | (7,370)us-gaap_ProfitLoss |
| Less: Net loss attributable to non-controlling interest | (479)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest | 0us-gaap_NetIncomeLossAttributableToNoncontrollingInterest |
| Net loss attributable to common shareholders | $ (12,056)us-gaap_NetIncomeLoss | $ (7,370)us-gaap_NetIncomeLoss |
| Basic and diluted net loss per common share | $ (0.31)us-gaap_EarningsPerShareBasicAndDiluted | $ (0.21)us-gaap_EarningsPerShareBasicAndDiluted |
| Weighted average common shares outstandingbasic and diluted | 38,574,702us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted | 35,900,596us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted |
| X | ||||||||||
|
- Definition
Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values also include the cost of borrowed funds accounted for as interest expense. No definition available.
|
| X | ||||||||||
|
- Definition
Represents the value of change in fair value of short term investments. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|